Spruce, HMNC Brain Health announce first patient dosed in Phase 2 TAMARIND trial

HMNC Brain Health, in collaboration with Spruce Biosciences (SPRB), announced that the first patient has been dosed in the Phase 2 clinical trial called “Tildacerfont as Antidepressant Medication and Relief in Depression”. TAMARIND is evaluating tildacerfont, a corticotropin-releasing factor type 1 receptor antagonist, as a potential treatment for major depressive disorder in patients selected using HMNC’s proprietary investigational-stage patient selection tool. TAMARIND targets a biologically distinct subtype of MDD patients tied to hypothalamic-pituitary-adrenal axis dysregulation. Tildacerfont has the potential to address hyperactive brain corticotropin-releasing factor neurotransmission and aberrant functioning of the HPA axis in patients with MDD by blocking the CRF1 receptor. Additionally, by utilizing genetic markers, HMNC’s patient selection tool aims to identify MDD patients who are more likely to respond to CRF1 receptor antagonism. Topline results from TAMARIND are anticipated in the first half of 2026.